Anemia, Cancer
Conditions
Keywords
Cancer-related anemia
Brief summary
The purpose of this study is to evaluate the efficacy of darbepoetin alfa versus placebo in reducing the occurrences of red blood cell transfusions in subjects with anemia of cancer who are not receiving chemotherapy.
Interventions
DRUGDarbepoetin Alfa
6.75 mcg/kg Q4W
DRUGPlacebo
Placebo Q4W
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* subjects with non-myeloid malignancies * anemia due to cancer * ECOG status 0 to 2 * greater than or equal to 4-month expectancy * greater than or equal to 18 years and of legal age for informed consent * screening hemoglobin concentration less than or equal to 11.0g/dL * adequate serum folate and vitamin B12 * adequate renal and liver function * written informed consent
Exclusion criteria
* subjects currently receiving or planned to receive cytotoxic chemotherapy or myelosuppressive radiotherapy during the study or within 4 weeks before randomization * in complete remission, as determined by the investigator * subjects who have other diagnoses not related to the cancer which cause anemia (eg. gastrointestinal bleeding, renal disease, etc) * documented history of pure red cell aplasia * Known history of seizure disorder * cardiac condition: uncontrolled angina, congestive heart failure, known ejection fraction less than 40%, or uncontrolled cardiac arrhythmia * uncontrolled hypertension * clinically significant systemic infection or chronic inflammatory disease present at the time of randomization * iron deficiency * known positive test for HIV infection * previously suspected of or confirmed to have neutralizing antibodies to rHuEPO or darbepoetin alfa * received rHuEPO or darbepoetin alfa therapy within 4 weeks of randomization * less than 30 days since receipt of any investigational drug or device that is not approved by the applicable regulatory authority * pregnant or breast feeding * subject of reproductive potential who is not using adequate contraceptive precautions * known hypersensitivity to mammalian-derived product or any other ingredients in the investigational product * previously randomized into this study * concerns for subject's compliance with the protocol procedures
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrences of red blood cell transfusion | from study day 29 (week 5) to week 17 |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of first red blood cell transfusion | from week 5 (study day 29) to week 17 (study day 119) |
| Change in hemoglobin concentration measured | from baseline (study day 1) to EOTP |
| Adverse events and serious adverse events | throughout study for subjects who received at least 1 dose of investigational product |
| Survival | deaths on study and deaths in long-term follow-up period for subjects who received at least 1 dose of investigational product |
| Incidence, if any, of neutralizing antibody formation to investigational product | throughout study for subjects who received at least 1 dose of investigational product |
Outcome results
None listed